BioCryst PharmaceuticalsBCRX
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 580
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
42% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $8.5M
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
6% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 32
0% less funds holding
Funds holding: 256 [Q3] → 255 (-1) [Q4]
4% less capital invested
Capital invested by funds: $1.31B [Q3] → $1.26B (-$50M) [Q4]
2.45% less ownership
Funds ownership: 83.37% [Q3] → 80.93% (-2.45%) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 90
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
38%
upside
Avg. target
$18.40
131%
upside
High target
$30
277%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams 6% 1-year accuracy 4 / 69 met price target | 38%upside $11 | Outperform Reiterated | 11 Apr 2025 |
Needham Serge Belanger 40% 1-year accuracy 49 / 123 met price target | 88%upside $15 | Buy Reiterated | 10 Apr 2025 |
Citizens Capital Markets Jonathan Wolleben 34% 1-year accuracy 23 / 67 met price target | 126%upside $18 | Market Outperform Reiterated | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 26% 1-year accuracy 93 / 355 met price target | 277%upside $30 | Buy Reiterated | 25 Feb 2025 |
JMP Securities Jonathan Wolleben 34% 1-year accuracy 23 / 67 met price target | 126%upside $18 | Market Outperform Reiterated | 31 Jan 2025 |
Financial journalist opinion
Based on 4 articles about BCRX published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
BioCryst to Report First Quarter 2025 Financial Results on May 5
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025.
Positive
Zacks Investment Research
1 week ago
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Neutral
GlobeNewsWire
2 weeks ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 weeks ago
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET.
Neutral
GlobeNewsWire
1 month ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 month ago
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Zacks Investment Research
1 month ago
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Seeking Alpha
1 month ago
BioCryst: Orladeyo's Expansion Is Just Getting Started
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, BioCryst's improved operating metrics and strategic focus on key assets like BCX17725 and avoralstat signal disciplined resource allocation and long-term growth. ORLADEYO's potential pediatric expansion could significantly boost market penetration and revenue, positioning BioCryst as a leader in hereditary angioedema treatment.
Positive
Seeking Alpha
1 month ago
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats.
Charts implemented using Lightweight Charts™